For decades, women diagnosed with triple-negative breast cancer have faced one of the most demanding treatment journeys in oncology, typically receiving a punishing combination of chemotherapy drugs that includes anthracyclines, agents known for both their potency and their long-term harms. A major new real-world study now suggests that one of the most toxic components of that regimen may be dispensable for many patients, even in the era of modern immunotherapy. The findings, drawn from electronic health records of more than 870 women treated across the United States between 2012 and 2024, indicate that adding anthracyclines to a carboplatin-based chemotherapy backbone does not improve the likelihood of achieving a pathologic complete response, a milestone strongly linked to long-term survival. The research was published in the journal Breast Cancer Research and Treatment.
Triple-negative breast cancer, defined by the absence of estrogen receptor and progesterone receptor expression and the lack of HER2 amplification, accounts for roughly 10 to 15 percent of all breast cancers but carries a disproportionate share of early recurrences and deaths. Because the tumor lacks the molecular targets that make other breast cancer subtypes vulnerable to endocrine therapy or HER2-directed drugs, cytotoxic chemotherapy has remained the backbone of treatment. Historically, anthracycline-and-taxane regimens have been the standard of care, producing pathologic complete response rates of roughly 37 to 41 percent. When patients achieve a pathologic complete response, meaning no residual invasive cancer is found in the breast or lymph nodes at the time of surgery, their five-year event-free survival approaches 90 percent, compared with 57 percent for those who do not. That makes the response a powerful surrogate for cure and a critical endpoint for evaluating treatment strategies.
The trouble with anthracyclines lies in what they leave behind. Pooled data from randomized controlled trials show that patients treated with anthracycline-containing regimens face more than a five-fold higher risk of clinical cardiotoxicity, as well as sharply elevated risks of acute myeloid leukemia and myelodysplastic syndrome. Long-term follow-up studies in breast cancer survivors have documented heart failure, arrhythmias, and secondary blood cancers years or decades after the original diagnosis. For young women facing the prospect of decades of survival after successful breast cancer treatment, these late effects are not trivial side effects; they are life-altering or life-shortening complications in their own right. Reducing or eliminating anthracycline exposure without sacrificing cancer control has therefore become one of the most consequential questions in early breast cancer management.
At the same time, the treatment landscape has been transformed by two major developments. The first is the incorporation of carboplatin, a platinum chemotherapy agent, into neoadjuvant regimens. Trials such as GeparSixto, CALGB 40603, and BrighTNess demonstrated that adding carboplatin increases pathologic complete response rates in triple-negative disease, although often at the cost of substantially more hematologic toxicity, treatment delays, and dose reductions. The second development is immunotherapy. The landmark KEYNOTE-522 trial established perioperative pembrolizumab, an antibody that blocks the PD-1 immune checkpoint, combined with neoadjuvant chemotherapy as the new standard of care for stage II and III disease, improving both pathologic complete response and overall survival. Yet real-world experience with that regimen has revealed higher-than-anticipated immune-related adverse events, frequent discontinuation, and dose reductions, raising concerns about how much drug burden patients can realistically tolerate.
Against this shifting backdrop, a research team led by investigators at the University of Iowa and the University of Wisconsin, working with the Greater Plains Collaborative, a PCORnet clinical research network spanning ten medical centers across nine states, asked a deceptively simple question: in actual clinical practice, does adding anthracyclines to carboplatin plus taxane chemotherapy improve outcomes? They compared two regimens among women with stage I to III triple-negative breast cancer diagnosed between 2012 and 2024. The first, abbreviated CbT, consisted of carboplatin plus a taxane. The second, AC-CbT, added doxorubicin plus cyclophosphamide, the classic anthracycline combination. The primary outcome was pathologic complete response as recorded in hospital cancer registries by treating physicians, supplemented where necessary by comparisons of pre-treatment clinical staging and post-surgical pathologic staging.
The results were striking in their clarity. Among the 878 women analyzed, 41.2 percent received the anthracycline-free CbT regimen and 58.8 percent received AC-CbT. Half of the entire cohort achieved a pathologic complete response. On the surface, the anthracycline group appeared to fare slightly better, with response rates of 51.9 percent versus 47.2 percent for CbT, but this difference was not statistically significant. More importantly, after multivariable adjustment using inverse probability weighting, accounting for age, stage, grade, race, body mass index, comorbidity, treatment site, and pembrolizumab use, the addition of anthracyclines conferred no meaningful advantage, with an adjusted odds ratio of 1.05 and a confidence interval spanning 0.69 to 1.59. Sensitivity analyses that reclassified ambiguous response data or excluded those cases entirely produced the same conclusion.
What did predict response? Pembrolizumab use nearly doubled the odds of pathologic complete response, with an adjusted odds ratio of 1.97. Higher-grade tumors were more likely to respond, paradoxically, with grade 3 disease carrying nearly twice the odds of grade 1 or 2 tumors, a pattern consistent with the principle that the most biologically aggressive cancers are often the most sensitive to chemotherapy. Lower stage predicted higher response, as expected, and women diagnosed between ages 40 and 49 were roughly twice as likely to respond as those diagnosed at 60 or older, a finding the investigators probed extensively with post hoc and machine-learning analyses without uncovering an obvious explanation. Notably, an interaction analysis showed no evidence that anthracyclines mattered more or less depending on whether pembrolizumab was given, suggesting the anthracycline question remains unresolved in both the immunotherapy era and outside it.
The study also documents a dramatic practice transformation. Among all 2,413 triple-negative breast cancer patients in the underlying dataset, use of any carboplatin-containing regimen rose from 7.1 percent in 2012 to 72.8 percent in 2024. Pembrolizumab uptake was swift following the 2021 publication of KEYNOTE-522 results, and by the end of the study period, 46 percent of the analytic cohort had received it, concentrated overwhelmingly in the anthracycline-containing group. Interestingly, the data reveal how oncologists tailor care in the real world: older patients and those with comorbidities were more likely to forgo anthracyclines, while those with stage III, more aggressive disease were more likely to receive all four cytotoxic drug classes. Nearly a third of patients received combinations that had never appeared in clinical guidelines, reflecting deliberate individualized risk-benefit balancing rather than rigid protocol adherence.
Perhaps most provocative is the finding that carboplatin has penetrated into stage I disease, a population excluded from KEYNOTE-522 and still recommended anthracycline-taxane therapy by National Comprehensive Cancer Network guidelines. Among all stage I patients in the dataset, 19.4 percent received carboplatin, rising from 3.4 percent in 2012 to 41.7 percent in 2024. Within the analytic cohort, stage I patients showed similar response rates with or without anthracyclines. This off-guideline adoption finds precedent in the adjuvant PATTERN trial, in which carboplatin plus paclitaxel matched anthracycline-based therapy in five-year overall survival, with three-quarters of enrolled patients having node-negative disease.
The investigators are careful to acknowledge limitations. As an observational study relying on electronic health records and registry data, it cannot exclude unmeasured confounding, and variables such as performance status, BRCA mutation status, treatment toxicity, adherence, and relative dose intensity were unavailable. Lower delivered doses in the four-drug regimen could theoretically explain the lack of anthracycline benefit, although the authors argue that real-world tolerability is itself a legitimate measure of a regimen’s worth. The cohort also lacked racial diversity, and a notable fraction of responses were classified as “not otherwise specified,” though sensitivity analyses confirmed the robustness of the central finding.
Even with those caveats, the study represents, to the authors’ knowledge, the largest real-world analysis of triple-negative breast cancer spanning the immunotherapy era, and it provides the strongest real-world evidence yet that anthracyclines may not earn their place alongside carboplatin-based chemoimmunotherapy. Ongoing randomized trials, most notably the SCARLET trial evaluating anthracycline-free chemoimmunotherapy against the full KEYNOTE-522 regimen, will determine whether anthracycline omission can be definitively declared noninferior. Until then, this research shifts the burden of proof: the question is no longer whether patients can safely be spared anthracyclines, but whether the drugs still have anything left to offer.
Subject of Research: Anthracycline-containing versus anthracycline-free carboplatin-based regimens in early-stage triple-negative breast cancer: real-world outcomes
Article Title: Anthracycline-containing versus anthracycline-free carboplatin-based regimens in early-stage triple-negative breast cancer: real-world outcomes
Article References: Kroll, M. R., Schroeder, M. C., Neuner, J. M., Viyyuri, B. R., Ravindra, A., McDougall, D., Chapman, C. G., Fleege, N. M. G., Chrischilles, E. A., Song, X., & Phadke, S. (2026). Anthracycline-containing versus anthracycline-free carboplatin-based regimens in early-stage triple-negative breast cancer: real-world outcomes. Breast Cancer Research and Treatment, 219(2), Article 7. https://doi.org/10.1007/s10549-026-08071-8
Image Credits: AI Generated
DOI: 10.1007/s10549-026-08071-8
Keywords: Anthracycline-containing, versus, anthracycline-free, carboplatin-based, regimens, early-stage, triple-negative, breast, cancer, real-world, outcomes, scientific research
Cite Scienmag News
APA MLA Chicago
Nathaniel Bowman. (September 12, 2026). Anthracycline-containing versus anthracycline-free carboplatin-based regimens in early-stage triple-negative breast cancer: real-world outcomes. Scienmag. https://scienmag.com/anthracycline-containing-versus-anthracycline-free-carboplatin-based-regimens-in-early-stage-triple-negative-breast-cancer-real-world-outcomes/
Nathaniel Bowman. “Anthracycline-containing versus anthracycline-free carboplatin-based regimens in early-stage triple-negative breast cancer: real-world outcomes.” Scienmag, 12 September 2026, https://scienmag.com/anthracycline-containing-versus-anthracycline-free-carboplatin-based-regimens-in-early-stage-triple-negative-breast-cancer-real-world-outcomes/. Accessed 12 September 2026.
Nathaniel Bowman. “Anthracycline-containing versus anthracycline-free carboplatin-based regimens in early-stage triple-negative breast cancer: real-world outcomes.” Scienmag. September 12, 2026. https://scienmag.com/anthracycline-containing-versus-anthracycline-free-carboplatin-based-regimens-in-early-stage-triple-negative-breast-cancer-real-world-outcomes/
Copy citation Download RIS
Tags: Anthracycline-containinganthracycline-freeanthracycline-free regimensbreastbreast cancer treatment comparisoncancercarboplatin-basedcarboplatin-based treatmentchemotherapychemotherapy toxicity and efficacyearly-stageearly-stage triple-negative breast cancerelectronic health record studyimmunotherapy in TNBClong-term toxicity of anthracyclinesoutcomespathologic complete responsereal-worldreal-world clinical outcomesregimensScientific Researchtriple-negativetriple-negative breast cancerversus
